Charis Eng

Charis Eng

Auto-generated profile, based on publicly available information

Charis Eng

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1997 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DLDanny Liaw
Danny Liaw
DMDebbie J. Marsh
Debbie J. Marsh
JLJing Li
Jing Li
PDPatricia L. M. Dahia
Patricia L. M. Dahia
SWSteven I. Wang
Steven I. Wang
RPRamon Parsons
Ramon Parsons

1 June 1993 in Nature
Verified
Journal Article
Closed access
LMLois M. Mulligan
Lois M. Mulligan
John B. KwokJohn B. Kwok
John B. Kwok
CHCatherine S. Healey
Catherine S. Healey
MEMark J. Elsdon
Mark J. Elsdon
CECharis Eng
Charis Eng
BPBruce A. J. Ponder
Bruce A. J. Ponder

9 May 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HNHartmut P.H. Neumann
Hartmut P.H. Neumann
BBBirke Bausch
Birke Bausch
SMSarah R. McWhinney
Sarah R. McWhinney
BBBernhard U. Bender
Bernhard U. Bender
OGOliver Gimm
Oliver Gimm
CECharis Eng
Charis Eng
The group of susceptibility genes for pheochromocytoma that included the proto-oncogene RET (associated with multiple endocrine neoplasia type 2 [MEN-2]) and the tumor-suppressor gene VHL (associated with von Hippel–Lindau disease) now also encompasses the newly identified genes for succinate dehydrogenase subunit D (SDHD) and succinate dehydrogenase subunit B (SDHB), which predispose carriers to pheochromocytomas and glomus tumors. We used molecular tools to classify a large cohort of patients with pheochromocytoma with respect to the presence or absence of mutations of one of these four genes and to investigate the relevance of genetic analyses to clinical practice. Peripheral blood from unrelated, consenting registry patients with pheochromocytoma was tested for mutations of RET, VHL, SDHD, and SDHB. Clinical data at first presentation and follow-up were evaluated. Among 271 patients who presented with nonsyndromic pheochromocytoma and without a family history of the disease, 66 (24 percent) were found to have mutations (mean age, 25 years; 32 men and 34 women). Of these 66, 30 had mutations of VHL, 13 of RET, 11 of SDHD, and 12 of SDHB. Younger age, multifocal tumors, and extraadrenal tumors were significantly associated with the presence of a mutation. However, among the 66 patients who were positive for mutations, only 21 had multifocal pheochromocytoma. Twenty-three (35 percent) presented after the age of 30 years, and 17 (8 percent) after the age of 40. Sixty-one (92 percent) of the patients with mutations were identified solely by molecular testing of VHL, RET, SDHD, and SDHB; these patients had no associated signs and symptoms at presentation. Almost one fourth of patients with apparently sporadic pheochromocytoma may be carriers of mutations; routine analysis for mutations of RET, VHL, SDHD, and SDHB is indicated to identify pheochromocytoma-associated syndromes that would otherwise be missed.

1 June 2009 in Thyroid®
Verified
Journal Article
Closed access
R(Richard T. Kloos (Chair)
Richard T. Kloos (Chair)
CECharis Eng
Charis Eng
DEDouglas B. Evans
Douglas B. Evans
GFGary L. Francis
Gary L. Francis
RGRobert F. Gagel
Robert F. Gagel
SWSamuel A. Wells
Samuel A. Wells
Background: Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medicine and the knowledge and experience of a panel of expert clinicians. Methods: Relevant articles were identified using a systematic PubMed search and supplemented with additional published materials. Evidence-based recommendations were created and then categorized using criteria adapted from the United States Preventive Services Task Force, Agency for Healthcare Research and Quality. Results: Clinical topics addressed in this scholarly dialog included: initial diagnosis and therapy of preclinical disease (including RET oncogene testing and the timing of prophylactic thyroidectomy), initial diagnosis and therapy of clinically apparent disease (including preoperative testing and imaging, extent of surgery, and handling of devascularized parathyroid glands), initial evaluation and treatment of postoperative patients (including the role of completion thyroidectomy), management of persistent or recurrent MTC (including the role of tumor marker doubling times, and treatment of patients with distant metastases and hormonally active metastases), long-term follow-up and management (including the frequency of follow-up and imaging), and directions for future research. Conclusions: One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice.

1 July 2001 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
DADewi Astuti
Dewi Astuti
FLFarida Latif
Farida Latif
ADAshraf Dallol
Ashraf Dallol
PDPatricia L.M. Dahia
Patricia L.M. Dahia
FDFiona Douglas
Fiona Douglas
EMEamonn Richard Maher
Eamonn Richard Maher

1 January 2007 in Cell
Verified
Journal Article
Closed access
WSWen H. Shen
Wen H. Shen
ABAdayabalam S. Balajee
Adayabalam S. Balajee
JWJianli Wang
Jianli Wang
HWHong Wu
Hong Wu
CECharis Eng
Charis Eng
YYYuxin Yin
Yuxin Yin